Life Sciences

  • January 14, 2026

    Pharma Co. Consultant Charged With Insider Trading

    A New Jersey man is facing securities fraud charges after using his access to drug trial results for a Boston-area pharmaceutical company to make nearly $500,000 in profits, federal prosecutors say.

  • January 14, 2026

    Cannabis Co. Says Rivals Infringe Distillation Patents

    Natural Extraction Systems LLC has launched lawsuits against several makers of THC-infused products in federal courts, alleging that they have infringed four of its patents to create their products.

  • January 13, 2026

    La. Moves To Extradite Calif. Doc Over Abortion Pill Trafficking

    Louisiana Gov. Jeff Landry on Tuesday said he would authorize an extradition request for a California doctor accused of illegally mailing abortion pills to a Louisiana resident, further escalating a legal battle over the reach of state bans in the post-Roe era.

  • January 13, 2026

    Medical Device Co. Faces New Derivative Suit In Delaware

    A stockholder of digital health equipment business Butterfly Network Inc. launched a derivative suit in Delaware's Court of Chancery on Tuesday, seeking recovery for the company of "many millions" tied to allegedly misleading disclosures ahead of a special purpose acquisition company take-public merger in 2021.

  • January 13, 2026

    US Patent Applications Plunge After Years Of Growth

    The number of patent applications filed in the U.S. dropped 9% in 2025 to the lowest level since 2019 after seven years of growth, and the number of granted applications also declined slightly, according to a report released Tuesday.

  • January 13, 2026

    Squires Institutes 8 Patent Reviews, Rebuffs 47 Petitions

    U.S. Patent and Trademark Office Director John Squires has denied 47 requests for America Invents Act patent reviews and granted eight other petitions, continuing his practice of spurning most patent challenges that reach his desk since he took over the handling of institution decisions.

  • January 13, 2026

    Beasley Allen Talc Work Sends 'Bad Signal,' J&J Says

    Johnson & Johnson's talc unit told a New Jersey appeals panel on Tuesday that a lower court's ruling permitting Beasley Allen Law Firm attorneys to represent plaintiffs in multicounty litigation over its talc-based baby powder "sends a very bad signal" to the state bar.

  • January 13, 2026

    Express Scripts Can't Impel FTC Atty Views On Insulin Makers

    A Federal Trade Commission in-house judge has denied a bid from Express Scripts to force a commission attorney to sit for a deposition to discuss an investigation into insulin manufacturers as the pharmacy benefit manager defends against the agency's insulin pricing case.

  • January 13, 2026

    J&J Wins Partial Reversal Of $1B Merger Milestone Loss

    Delaware's Supreme Court has partially reversed a vice chancellor's September 2024 ruling that Johnson & Johnson owes more than $1 billion for failing to prioritize regulatory approvals linked to "earnout" payments for robotic surgical device technology that J&J acquired from a developer.

  • January 12, 2026

    CareFirst Opposes J&J's Bid To Revisit Stelara Antitrust Case

    Insurer CareFirst urged a Virginia federal court to reject Johnson & Johnson's bid for reconsideration of a ruling that refused to toss antitrust and patent fraud claims over the immunosuppressive drug Stelara.

  • January 12, 2026

    The Curious, Very Long Delay In A Pioneering Drug Prices Suit

    When Merck & Co. launched a fiery challenge to Medicare's landmark drug price negotiations, it blazed a trail for many similar suits. But 31 months later, the challenge is stalled where it started as Merck begs for a ruling, other suits speed along the path it created and huge costs now seem unavoidable.

  • January 12, 2026

    Del. Jurist Cites 'Troubling' Questions In Cashout Suit

    A Delaware vice chancellor described as "troubling" on Monday unsettled questions in a stockholders' amended suit alleging an unfair recapitalization that allegedly forced out Bioventix Inc. common stockholders for a penny per share ahead of a new financing, asking how much discovery had been taken before filing of the complaint.

  • January 12, 2026

    Terumo Plaintiff Settles, Drops Cancer Case Before Trial

    One of the two plaintiffs set to take their case to trial this month against Terumo BCT Inc. accusing the company of causing their cancer reached a stipulation to dismiss his case with prejudice Friday, according to court records.

  • January 12, 2026

    Del. Court Blocks Presuit Damages On Agilent Patent

    A Delaware federal court ruled that laboratory equipment company Agilent Technologies couldn't collect damages for any alleged infringement of one of its patents prior to the filing of its intellectual property lawsuit against biotechnology business Axion BioSystems.

  • January 12, 2026

    Feds To Drop Appeal In 340B Rebate Pilot Challenge

    The U.S. Department of Health and Human Services on Monday suggested it will end its appeal of a First Circuit order temporarily blocking it from instituting a rebate program that would change how the agency distributes payments in the federal 340B drug discount program that provides medications at reduced costs to low-income Americans. 

  • January 12, 2026

    Sidley-Led Smith & Nephew Inks $450M Orthopaedics Deal

    Sidley Austin-advised Smith & Nephew said Monday it will acquire Gunderson Dettmer-led U.S. sports medicine company Integrity Orthopaedics and its Tendon Seam rotator cuff repair technology in a deal valued at up to $450 million.

  • January 12, 2026

    Medicine Biz Mirador Wraps $250M Funding Round

    San Diego-based clinical-stage precision medicine company Mirador Therapeutics Inc. announced Monday that it closed its Series B funding round with $250 million of investor commitments, bringing the company's total capital raised since its March 2024 launch to more than $650 million.

  • January 12, 2026

    Justices Want SG Input On Arthritis Drug Competition Fight

    The U.S. Supreme Court on Monday asked the Trump administration to weigh in on whether state unfair competition claims should be used to block a competitor from selling compounded versions of drugs in certain states.

  • January 12, 2026

    No High Court Review For California Opioid 'Nuisance' Suit

    The U.S. Supreme Court on Monday said it would not weigh in on a circuit court decision that a California public nuisance lawsuit against pharmacy benefit managers over their opioid-dispensing practices belongs in state court.

  • January 12, 2026

    Justices Won't Weigh Collective Cert. Process In Eli Lilly Case

    The U.S. Supreme Court declined on Monday to review whether courts should stick with a long-standing two-step analysis for certifying collective actions in an age discrimination case against Eli Lilly and Co. that could have affected wage and hour litigation.

  • January 09, 2026

    Mylan, Aurobindo Must Face Generic Drug Price-Fixing Claims

    A Connecticut federal judge on Friday refused to hand a quick win to Mylan Pharmaceuticals and Aurobindo Pharma USA in sprawling antitrust litigation against 26 total pharmaceutical companies, ruling that a coalition of states has enough evidence to raise a genuine dispute about whether the companies conspired to fix drug prices.

  • January 09, 2026

    Squires Sets Precedent, Guidance On Discretionary Denials

    U.S. Patent and Trademark Office Director John Squires on Friday designated four decisions on discretionary denials at the Patent Trial and Appeal Board precedential and another nine informative.

  • January 09, 2026

    Biopharma Co. Secures D&O Coverage For Shareholder Suit

    A biopharmaceutical company is entitled to coverage for a suit alleging its board breached fiduciary duties under a pair of primary and excess directors and officers policies, a Delaware state court ruled, saying the suit is "meaningfully linked" to a previously noticed demand for books and records.

  • January 09, 2026

    Veterinary Group Says DOJ Accreditation Points Irrelevant

    The American Veterinary Medical Association has told a Tennessee federal court that the government's concerns about professional groups are irrelevant to a veterinary school's antitrust case challenging the association's accreditation requirements.

  • January 09, 2026

    Judge Denies 'Fatally Untimely' Bid For New Poaching Trial

    A Boston federal judge has denied what she called a "fatally untimely" motion for a new trial after a jury handed Cynosure LLC a $25 million verdict against two former employees who the company said caused other employees to breach their noncompete and nonsolicitation agreements.

Expert Analysis

  • 9th Circ.'s Trade Secrets Ruling Is A Win For DTSA Plaintiffs

    Author Photo

    The Ninth Circuit's recent decision in Quintara v. Ruifeng shifts the balance in federal trade secret litigation toward a more flexible, discovery-driven process, meaning that plaintiffs may be more likely to pursue claims under the Defend Trade Secrets Act, and early motions to strike or dismiss will face steep odds, say attorneys at Cooley.

  • Associates Can Earn Credibility By Investing In Relationships

    Author Photo

    As the class of 2025 prepares to join law firms this fall, new associates must adapt to office dynamics and establish credible reputations — which require quiet, consistent relationship-building skills as much as legal acumen, says Kyle Forges at Bast Amron.

  • Puzzling Out When Similar Insurance Claims Are Related

    Author Photo

    A recent decision in Virginia federal court shows that more than identical allegations of negligent business practices across two lawsuits may be necessary to satisfy the strict definition of relatedness under claims-made liability insurance policies, say attorneys at Hunton.

  • A Shifting Trend In FDA Form 483 Disclosure Obligations

    Author Photo

    A New York federal court's Checkpoint Therapeutics decision extends a recent streak of dismissals of securities class actions alleging that pharmaceutical companies failed to disclose U.S. Food and Drug Administration Form 483 inspection reports, providing critical guidance for companies during the FDA approval process, say attorneys at Alston & Bird.

  • Trending At The PTAB: IPR Memo And Its Fed. Circ. Backdrop

    Author Photo

    There are new rules for when and how evidence other than patents or printed publications can be considered in inter partes reviews, and while this change is intended to reflect current Federal Circuit precedent, the U.S. Patent and Trademark Office's memo seems to acknowledge tension with last month's Shockwave decision, say attorneys at Finnegan.

  • Lessons From 7th Circ.'s Deleted Chat Sanctions Ruling

    Author Photo

    The Seventh Circuit’s recent decision in Pable v. Chicago Transit Authority, affirming the dismissal of an ex-employee’s retaliation claims, highlights the importance of properly handling the preservation of ephemeral messages and clarifies key sanctions issues, says Philip Favro at Favro Law.

  • Breaking Down The Proposed Hemp Bill

    Author Photo

    A proposed bill in the U.S. House of Representatives, recently approved by the House Appropriations Committee, contains a rider that would significantly change the definition of hemp and dramatically reshape the current hemp-derived product market, say attorneys at King & Spalding.

  • Assessing Federal Securities Class Action Stats In '25 So Far

    Author Photo

    The settlement amount as a percentage of damages in securities class actions has continued to decline in the first half of 2025, a trend that may be important for assessing exposure and risk in future securities litigation, say analysts at Analysis Group.

  • Series

    Quilting Makes Me A Better Lawyer

    Author Photo

    Turning intricate patterns of fabric and thread into quilts has taught me that craftsmanship, creative problem-solving and dedication to incremental progress are essential to creating something lasting that will help another person — just like in law, says Veronica McMillan at Kramon & Graham.

  • How Agentic AI Is Testing The Limits Of Patent Law

    Author Photo

    While a recent Swiss court ruling suggests that human-centric rules regarding inventorship will likely remain in place for the near future, it captures a core tension confronting patent systems worldwide as the technology producing patent-worthy ideas is becoming increasingly autonomous, says Matthew Carey at Marshall Gerstein.

  • How To Prep For Potential Passage Of SAFER Banking Act

    Author Photo

    The Secure and Fair Enforcement Regulation, or SAFER, Banking Act, could fundamentally reshape how financial institutions interact with cannabis businesses, so operators that move now to get their house in order will be best positioned to capitalize if and when change comes, says Alex Leonowicz at Howard & Howard.

  • A Former PTAB Judge Weighs The End Of Remote Hearings

    Author Photo

    Former Patent Trial and Appeal Board Judge Amanda Wieker, now at McGuireWoods, examines the costs and benefits of the PTAB's impending in-person hearing requirement, and offers suggestions for making the most out of this new regime.

  • The Future Of Lab-Test Regs After FDA Rescinds Rule

    Author Photo

    The U.S. Food and Drug Administration recently rescinded its laboratory-developed tests rule in response to a Texas federal court decision this spring, reinforcing a separation of authority between the FDA and the Centers for Medicare & Medicaid Services, and calling into question the FDA's role in overseeing such tests without congressional action, say attorneys at Venable.

  • SDNY Ruling Reinforces Joint Steering Committee Obligations

    Author Photo

    The recent Southern District of New York decision in ChemImage v. Johnson & Johnson makes joint steering committees a valuable tool in strategic relationships, as provisions for such committees can now be wielded to demand attention to core issues, say Lisa Bernstein at the University of Chicago Law School, and Reginald Goeke and Brad Peterson at Mayer Brown.

  • What 2 Profs Noticed As Transactional Law Students Used AI

    Author Photo

    After a semester using generative artificial intelligence tools with students in an entrepreneurship law clinic, we came away with numerous observations about the opportunities and challenges such tools present to new transactional lawyers, say professors at Cornell Law School.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.